#16
|
||||
|
||||
ðàçâå âû êîìó-òî ÷òî-òî äîëæíû? è çà÷åì âàñ â ÷åì-òî óáåæäàòü?
|
#17
|
||||
|
||||
lissa, Âû ïðèâèâàëèñü îñåíüþ, â ñåçîí ÎÐÂÈ. Çàðàçèëèñü, çàáîëåëè. Áûâàåò.
Âàêöèíà ïðîòèâ ãðèïïà íà÷èíàåò äåéñòâîâàòü ÷åðåç 2-3 íåäåëè ïîñëå âàêöèíàöèè, è äåéñòâóåò (óáèòàÿ, êîòîðàÿ ââîäèòñÿ â âèäå èíúåêöèè) òîëüêî ïðîòèâ ñàìîãî ãðèïïà, êîòîðûé ïðåäñòàâëÿåò ñîáîé ó âçðîñëûõ çíà÷èòåëüíîå ìåíüøèíñòâî ÎÐÂÈ. Òîëüêî æèâàÿ ãðèïïîçíàÿ âàêöèíà îáåñïå÷èâàåò íåêîòîðóþ çàùèòó íå òîëüêî ïðîòèâ ãðèïïà, íî è ïðîòèâ äðóãèõ ÎÐÂÈ. Íî è åå äåéñòâèå òàêæå íà÷èíàåòñÿ ñïóñòÿ 2-3 íåäåëè ïîñëå âàêöèíàöèè. Ê ñîæàëåíèþ, ìû íå ìîæåì ñðàâíèòü Âàñ ïðèâèòóþ ñ Âàìè æå â òîò æå ãîä, íî íå ïðèâèòîé. Íî ìû ìîæåì ñðàâíèòü êîëëåêòèâ ïðèâèòûõ è êîëëåêòèâ íåïðèâèòûõ. Òàê âîò, â Ñâåðäëîâñêîé îáëàñòè áëàãîäàðÿ çíà÷èòåëüíîãî îõâàòà âàêöèíàöèåé ïðîòèâ ãðèïïà (äàæå òàêîé ñëàáîé âàêöèíîé, êàê ãðèïïîë) ãðóïï ðèñêà, íàïðèìåð, â 2003 ãîäó, åñëè ÿ ïðàâèëüíî ïîìíþ, óäàëîñü äîáèòüñÿ 3-êðàòíîãî ñíèæåíèÿ çàáîëåâàåìîñòè ãðèïïîì ïî ñðàâíåíèþ ñ ñîñåäíèìè îáëàñòÿìè. Ê ñîæàëåíèþ, âàêöèíàöèÿ îò ãðèïïà íå îáåñïå÷èâàåò 100% çàùèòû. Ïðèâèòîé ìîæåò çàáîëåòü ÎÐÂÈ (è äàæå ñ îñëîæíåíèåì) è äàæå ñàìèì ãðèïïîì. Ñàì ãðèïï, ïðàâäà, ïðè ýòîì ïðîòåêàåò ëåã÷å è îñëîæíåíèÿ ìåíåå âåðîÿòíû - íî îïÿòü æå, ýòî äàííûå äëÿ ïîïóëÿöèé. Ëè÷íî Âàì 100% ýôôåêòèâíîñòè ïðèâèâêè íèêòî ãàðàíòèðîâàòü, ê ñîæàëåíèþ, íå ìîæåò. Åäèíñòâåííîå, ÷òî ìîæíî ñêàçàòü, - ÷òî áîëåëè Âû íå èç-çà òîãî, ÷òî ïðèâèâàëèñü. Ïîïðîáóéòå íà ñëåäóþùèé ãîä (ñåé÷àñ óæå ïîçäíîâàòî) æèâóþ èíòðàíàçàëüíóþ âàêöèíó, åñëè ó Âàñ íåò õðîíè÷åñêîãî íàñìîðêà. Òîëüêî ïîñòàðàéòåñü ïðèâèòüñÿ â êîíöå ñåíòÿáðÿ - íà÷àëå îêòÿáðÿ. P. S. À íà÷èíàòü ïðåäëîæåíèÿ ñ ïðîïèñíîé áóêâû è èñïîëüçîâàòü çíàêè ïðåïèíàíèÿ Âàì ñëîæíî, äà? Èëè ýòî ïðîñòî òàêîé ñïîñîá âûðàçèòü íåóâàæåíèå ê ïðèñóòñòâóþùèì íà ôîðóìå? |
#18
|
|||
|
|||
Êàê ÿ ÷óòü íå ñòàë â ñòðîé àíòèïðèâèâî÷íèêîâ
Íàìåäíè, êàê ÿ óæå è ñîîáùàë, ïðèâèë ñåìåéñòâî æèâîé âàêöèíîé ïðîòèâ ãðèïïà. Ïåðåíîñèìîñòü áûëà çàìå÷àòåëüíàÿ. Íà 4 äåíü ó ðåáåíêà (8 ëåò) îñòðî ïîäíÿëàñü òåìïåðàòóðà äî 39 ãðàäóñîâ, èíòîêñèêàöèÿ, ïîÿâèëèñü íå îñîáî âûðàçèòåëüíûå êàòàðàëüíûå ÿâëåíèÿ.
 êðóã äèàãíîñòè÷åñêîãî ïîèñêà áûëà, ðàçóìååòñÿ, áûëà âêëþ÷åíà è ïîñòâàêöèíàëüíàÿ ðåàêöèÿ. Îòâåò ïîÿâèëñÿ íà 4 äåíü, êîãäà âîçíèêëà õàðàêòåðíàÿ ñûïü. Ýòî áûëà êðàñíóõà |
#19
|
||||
|
||||
Ò. ê. ÿ â òå÷åíèå ïîñëåäíèõ 8 ëåò ãðèïïîì íå áîëåë è â ãðóïïû ðèñêà ïîêà íå âõîæó, òî ÿ îò ïðèâèêè îò ãðèïïà âîçäåðæóñü.
|
#20
|
||||
|
||||
[P. S. À íà÷èíàòü ïðåäëîæåíèÿ ñ ïðîïèñíîé áóêâû è èñïîëüçîâàòü çíàêè ïðåïèíàíèÿ Âàì ñëîæíî, äà? Èëè ýòî ïðîñòî òàêîé ñïîñîá âûðàçèòü íåóâàæåíèå ê ïðèñóòñòâóþùèì íà ôîðóìå?[/quote]
Ìíå ñîâåðøåííî íå ñëîæíî. Ñ÷èòàéòå, ÷òî ýòî áûëî õîêó. Ýòàêèé êðèê äóøè. Òî åñòü Âû õîòèòå ñêàçàòü, ÷òî íèêàêîé ïðÿìîé ñâÿçè ìåæäó íåêèì èçìåíåíèåì èììóíèòåòà, âûçûâàåâûì âàêöèíàöèåé è ìîåé ïíåâìîíèåé íåò? ß áû ïîâåðèëà. Íî ó íàñ áîëüøîé êîëëåêòèâ. 100% âàêöèíàöèÿ â ïðîøëîì ãîäó ïî÷òè âñåõ îòïðàâèëà ñ òåì èëè èíûì îñëîæíåíèåì ÎÐÂÈ íà áîëüíè÷íûé. Âñå çäîðîâûå âçðîñëûå ëþäè, ïðîøó çàìåòèòü ñ ìåäèöèíñêèì îáðàçîâàíèåì è äàæå ñòåïåíÿìè.  ýòîì ãîäó 70% îò âàêöèíàöèè îòêàçàëèñü. ß ÷åñòíî æàëåþ, ÷òî íå ñäåëàëà òîãî æå... Ìîæåò äåëî â êà÷åñòâå è õàðàêòåðå âàêöèíû. Ïîêà, íàïðèìåð, ÿ ïðèâèâàëàñü ôëþàðèêñîì -ïðîáëåì íå áûëî. Âû êàê èíôåêöèîíèñò, ÷òî ìîæåòå ñêàçàòü ïðî àãðèïïàë è âàêñèãðèïï? |
#21
|
|||
|
|||
Öèòàòà:
|
#22
|
|||
|
|||
Öèòàòà:
Prevention and Control of Influenza Recommendations of the Advisory Committee on Immunization Practices (ACIP) ... Health-Care Workers and Other Persons Who Can Transmit Influenza to Those at High Risk Persons who are clinically or asymptomatically infected can transmit influenza virus to persons at high risk for complications from influenza. Decreasing transmission of influenza from caregivers and household contacts to persons at high risk might reduce influenza-related deaths among persons at high risk. In two studies, vaccination of health-care workers was associated with decreased deaths among nursing home patients (144,145), and hospital-based influenza outbreaks frequently occur where unvaccinated health-care workers are employed. Administration of LAIV has been demonstrated to reduce MAARI in contacts of vaccine recipients (175,176) and to reduce ILI-related economic and medical consequences (such as work days lost and number of health-care provider visits). All health-care workers should be vaccinated against influenza annually (147,177,178). Facilities that employ health-care workers are strongly encouraged to provide vaccine to workers by using approaches that maximize vaccination levels. An improvement in vaccination coverage levels might help to protect health-care workers, their patients, and communities; improve prevention of influenza-associated disease and patient safety; and reduce disease burden. Influenza vaccination levels among health-care workers should be regularly measured and reported. Although vaccination levels for health-care workers are typically <40%, with moderate effort, organized campaigns can attain higher levels of vaccination among this population (146,179). In 2005, seven states had legislation requiring annual influenza vaccination of health-care workers or the signing of an informed declination (147), and 15 states had regulations regarding vaccination of health-care workers in long-term--care facilities (180). Physicians, nurses, and other workers in both hospital and outpatient-care settings, including medical emergency-response workers (e.g., paramedics and emergency medical technicians), should be vaccinated, as should employees of nursing home and chronic-care facilities who have contact with patients or residents. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
|
#23
|
|||
|
|||
Öèòàòà:
|
#24
|
||||
|
||||
äîáðûé äåíü
ÿ ìîæåò ãëóïûé âîïðîñ çàäàì , íî ìîæåò ëè íà âàêöèíó èíôëþâàê ðàçâèòñÿ ïîáî÷íàÿ ðåàêöèÿ â âèäå ïðîñòóäû, äîïñóòèì ë¸ãêèé íàñìîðê. åñëè äà, òî ìîãó ëè ÿ çàðàçèòü äðóãèõ? |
#25
|
||||
|
||||
Öèòàòà:
Ïîñêîëüêó âàêöèíà Èíôëþâàê ïðåäñòàâëÿåò ñîáîé íàáîð îòäåëüíûõ áåëêîâ (ãåìàããëþòèíèíà) íåñêîëüêèõ òèïîâ âèðóñà ãðèïïà è íå ñîäåðæèò æèçíåñïîñîáíûõ âèðóñîâ, íèêîãî çàðàçèòü Âû ïðèíöèïèàëüíî íå ìîæåòå. |
#26
|
|||
|
|||
Âàêöèíàöèÿ ïðîòèâ ãðèïïà
Óâàæàåìàÿ Lissa!
Ïðèâèâàòüñÿ èëè íåò îò ãðèïïà â êàæäûé ýïèäåìè÷åñêèé ïåðèîä - ýòî ëè÷íîå äåëî êàæäîãî ÷åëîâåêà. Íàñêîëüêî ÿ ïîíèìàþ äàííûé òîïèê îðãàíèçîâàí äëÿ îáìåíà îïûòà è èíôîðìàöèè ïî âàêöèíàì ïðîòèâ ãðèïïà ìåæäó âðà÷àìè, à íå äëÿ àãèòàöèè êîãî-íèáóäü çà âàêöèíàöèþ èëè ïðîòèâ.  Âàøåì ñëó÷àå íåîáõîäèìî ñìîòðåòü âàêöèíû, êîòîðûìè Âû ïðèâèâàëèñü. Íå íàêëàäûâàëñÿ ëè íà âàêöèíó ïðîäðîìàëüíûé ïåðèîä ÎÐÂÈ, êîíòàêòèðîâàëè ëè Âû â äåíü âàêöèíàöèè, åùå äî ðàçâèòèÿ îòâåòà èììóíîé ñèñòåìû ñ ÎÐÂÈ. Âû âåäü ýòîãî íå óêàçàëè, à ïðîñèòå Âàñ óáåäèòü â òîì, ÷òî íåîáõîäèìî ïðèâèâàòüñÿ â ýòîì ýïèä.ñåçîíå. Èçâèíèòå çà âîçìîæíûå ïîâòîðû, áîëüøèíñòâî îòâåòîâ íà Âàø âîïðîñû âû ïîëó÷èëè óæå íà 2-é ñòðàíèöå, ÿ æå ïèñàë Âàì îòâåò ïðî÷èòàâ Âàøå ïîñëàíèå íà 1-é ñòðàíèöå. |
#27
|
|||
|
|||
Ñèìïòîìû ñî ñòîðîíû íåðâíîé ñèñòåìû ó äåòåé ñ ãðèïïîì, âûçâàííûì âèðóñîì òèïà Â
NEUROLOGIC MANIFESTATIONS IN CHILDREN WITH INFLUENZA B VIRUS INFECTION [Brief Report] Pediatr Infect Dis J Volume 25(11) November 2006 pp 1081-1083 Lin, Chien-Hui MD*; Huang, Yhu-Chering MD, PhD*‡; Chiu, Cheng-Hsun MD, PhD*‡; Huang, Chung-Guei MS†‡; Tsao, Kuo-Chien MS†‡; Lin, Tzou-Yien MD*‡ From the *Division of Infectious Diseases, Department of Pediatrics, Chang Gung Children's Hospital, Taoyuan, Taiwan; †Department of Clinical Pathology, Chang Gung Memorial Hospital, Kweishan, Taoyuan, Taiwan; and the ‡College of Medicine, Chang Gung University, Kweishan, Taoyuan, Taiwan. Çà 29-ìåñÿ÷íûé ïåðèîä ó 11 (12%) èç 92 ãîñïèòàëèçèðîâàííûõ äåòåé ñ ãðèïïîì, âûçâàííûì âèðóñîì òèïà Â, îòìå÷àëèñü íåâðîëîãè÷åñêèå ñèìïòîìû. Âîçðàñò äåòåé ñîñòàâèë îò 1 ã. 5 ìåñ. äî 11 ëåò 3 ìåñ.  4-õ ñëó÷àÿõ îòìå÷àëèñü ôåáðèëüíûå ñóäîðîãè, â 7 ñëó÷àÿõ - ýíöåôàëîïàòèÿ/ýíöåôàëèò.  îòñóòñòâèå ñîîòâåòñòâóþùåé àíòèâèðóñíîé òåðàïèè âûçäîðîâëåíèå íàáëþäàëîñü ó 6 ïàöèåíòîâ, ó 1 ðåáåíêà îòìå÷åíû íåâðîëîãè÷åñêèå ïîñëåäñòâèÿ â âèäå êâàäðèïëåãèè è çàäåðæêè íåðâíî-ïñèõè÷åñêîãî ðàçâèòèÿ. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#28
|
|||
|
|||
Ïî ðåêîìåíäàöèè óâàæàåìûõ äîêòîðîâ ñàéòà è, îñîáåííî, áëàãîäàðÿ òåðïåëèâûì, ïîäðîáíûì è äîñòóïíûì ðàçúÿñíåíèÿì óâàæàåìîãî AlexGold â÷åðà âñåé ñåìü¸é ïðèâèëèñü îò ãðèïïà.
Ñîñòàâ ñåìüè: ðîäèòåëè ïî 35 ëåò, ðåáåíîê 8,5 ìåñ. Âàêöèíà: âàêñèãðèïï ñîîòâåòñòâåííî âçðîñëàÿ äîçà è äåòñêàÿ. Îùóùåíèÿ: ó íàñ ñ ìóæåì íåáîëüøàÿ áîëåçíåíîñòü â ìåñòå óêîëà ïðè íàæàòèè, ó ìåíÿ áûëà íåáîëüøàÿ ãîëîâíàÿ áîëü ïîñëå óêîëà, ÷òî âïîëíå ìîæåò áûòü è íå ñâÿçàíî ñ âàêöèíàöèåé. Ñïðàâî÷íî: â ðàéîííîé ïîëèêëèíèêå ðåáåíêó âåñüìà íàñòîé÷èâî, íî è áåñïëàòíî ïðåäëàãàëè ãðèïïîë, îò êîòîðîãî ìû ñ ïîìîùüþ âàøèõ êîíñóëüòàöèé îòêàçàëèñü.  êîììåð÷åñêèõ êëèíèêàõ ïðèâèâàòü ðåáåíêà ðàíüøå, ÷åì ïðîøåë ìåñÿö ñî äíÿ ïîñòàíîâêè ïðåäûäóùåé ïðèâèâêè (ïëàíîâûé ãåï. Â) òîæå íàîòðåç îòêàçàëèñü.. Ïðèøëîñü æäàòü. Îñîáîãî âûáîðà ìåæäó âàêöèíàìè â êîììåð÷åñêèõ öåíòðàõ íåò. Êîëÿò òî, ÷òî ó íèõ åñòü. Íåäåëþ. íàçàä áûë òîëüêî èíôëþâàê. Â÷åðà òîëüêî âàêñêèãðèïï. Íà ñåãîäíûøíèé äåíü: ñóòêè ïðîøëè - ïîë¸ò íîðìàëüíûé Ìàëûøó íà ïîâòîð ÷åðåç ìåñÿö. |
#29
|
|||
|
|||
Êëèíè÷åñêàÿ ýôôåêòèâíîñòü âàêöèíàöèè ïðîòèâ ãðèïïà ó âçðîñëûõ ñ äèàáåòîì
Diabetes Care 2006; 29(8):1771-1776
Clinical effectiveness of first and repeat influenza vaccination in adult and elderly diabetic patients Looijmans-Van den Akker I, Verheij TJ, Buskens E, Nichol KL, Rutten GE, Hak E. Julius Center for Health Sciences and Primary Health Care, University Medical Center, Utrecht, the Netherlands. OBJECTIVE: Influenza vaccine uptake remains low among the high-risk group of patients with diabetes, partly because of conflicting evidence regarding its potential benefits. We assessed the clinical effectiveness of influenza vaccination in adults with diabetes and specifically examined potential modification of effect by age and prior influenza vaccine uptake. RESEARCH DESIGN AND METHODS: The study was part of the Prevention of Influenza, Surveillance and Management (PRISMA) study, a nested case-control study conducted during the 1999-2000 influenza A epidemic, among 75,235 patients from primary care of any age recommended for vaccination. Among 9,238 adult patients with diabetes, 131 cases arose who were either hospitalized for diabetes dysregulation, acute respiratory disease, or cardiovascular disease and 61 cases who died, and we compared them with 1,561 control subjects. We evaluated the effect of (prior) influenza vaccination by means of logistic regression analysis controlling for age, sex, health insurance coverage, prior health care use, medication use, and comorbid conditions. RESULTS: Vaccination was associated with a 56% reduction in any complication (95% CI 36-70%), a 54% reduction in hospitalizations (26-71%), and 58% reduction in deaths (13-80%). Among study subjects aged 18-64 years, we observed somewhat higher reductions in the occurrence of any complication than among those aged >65 years (72 vs. 39%). In first-time vaccinated subjects, the primary end point was reduced by 47% (0.2-72%), and in those who received vaccination in the year before, the reduction was 58% (4-81%). CONCLUSIONS: Adults with type 2 diabetes, like other individuals from recognized risk groups, benefit considerably from influenza vaccination, and no difference in vaccine effectiveness was observed between first-time and repeat vaccination. Ïåðåâîä ðåçþìå âîñïîñëåäóåò. Ïîëíûé òåêñò ñòàòüè â ñâîáîäíîì äîñòóïå íà ñàéòå [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#30
|
|||
|
|||
Âàêöèíàöèÿ îò ãðèïïà è ðèñê ñìåðòè ó âçðîñëûõ, ãîñïèòàëèçèð. â ñâÿçè ñ ïíåâìîíèåé
Influenza Vaccination and Risk of Mortality Among Adults Hospitalized With Community-Acquired Pneumonia
Kimberly A. Spaude, MPH; Elias Abrutyn, MD; Cheryl Kirchner, RN, MS; Alex Kim, MS; Jennifer Daley, MD; David N. Fisman, MD, MPH, FRCP(C) Arch Intern Med 2007;167:53-59 Background. Influenza vaccination has been shown to reduce illness and all-cause mortality in vulnerable populations through the prevention of influenza infection. Attenuation of the severity of illness by vaccination has been reported for respiratory tract infections due to bacterial pathogens and would represent an important additional health benefit of influenza vaccination. We evaluated the impact of prior influenza vaccination on in-hospital mortality and other health outcomes among hospitalized adults with community-acquired pneumonia (CAP). Methods. Consecutive individuals hospitalized with CAP during "influenza season" (November to April, 1999-2003) at hospitals operated by Tenet HealthCare were identified using a database constructed to improve quality of patient care. Associations between vaccination status and all-cause in-hospital mortality were evaluated using logistic regression models. Results. Among 17 393 adults hospitalized with CAP during the study period, 1590 (19% of those with recorded vaccine status) had a history of influenza vaccination in the current or most recent influenza season. Vaccine recipients were less likely to die in hospital of any cause than individuals without vaccination (odds ratio, 0.30; 95% confidence interval, 0.22-0.41). These effects remained significant after adjustment for the presence of comorbid illnesses and pneumococcal vaccination (adjusted odds ratio for death, 0.61; 95% confidence interval, 0.43-0.87) and under widely varying assumptions about individuals with missing vaccination status. Conclusions. Prior influenza vaccination was associated with improved survival in hospitalized patients with CAP during influenza season. This observation, if confirmed by other studies, would represent an important additional benefit of enhanced influenza vaccine coverage. Author Affiliations: Drexel University School of Public Health (Ms Spaude and Dr Fisman) and College of Medicine (Drs Abrutyn and Fisman), Philadelphia, Pa; Department of Healthcare Quality, Tenet HealthSystem, Dallas, Tex (Ms Kirchner, Mr Kim, and Dr Daley); and Center for Health and Wellbeing, Princeton University, Princeton, NJ (Dr Fisman). Dr Fisman is now with the Child Health Evaluative Sciences, Research Institute of the Hospital for Sick Children, Toronto, Ontario. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Ïåðåâîä âîñïîñëåäóåò. |